17-Hydroxypregnenolone, Serum
17-hydroxypregnenolone is an intermediate product during the biosynthesis of steroid hormone in the adrenal gland and gonads. During the biosynthesis of steroid hormones, 17-α-hydroxylase converts pregnenolone to 17-hydroxypregnenolone and progesterone to 17-α-hydroxyprogesterone (17-OHP) in the zona glomerulosa and the zona reticularis. 17-hydroxypregnenolone is then activated by 3-β-hydroxysteroid dehydrogenase to form 17- hydroxyprogesterone. Therefore, the measurement of 17-hydroxypregnenolone provides valuable information in the diagnosis of various defects in enzymes involved in steroidogenesis, which is commonly referred as congenital adrenal hyperplasia (CAH).
17-α-hydroxylase deficiency (CYP17) is a rare cause of CAH resulting in an obstruction of cortisol biosynthesis. However, the accumulated intermediates are diverted to increase the synthesis of 11-Deoxycorticosterone (DOC), resulting in clinical symptoms of hypermineralocorticoidism including hypertension in later childhood. ACTH concentration increases in response to decrease in cortisol, which further elicits the mineralocorticoid overproduction. CYP17 mutations also influence sex steroid production in males in utero and in female at the time of puberty as this enzyme is also responsible for converting 17-hydroxypregnenolone to dehydroepiandrosterone (DHEA) and 17-OHP to androstenedione. On the other hand, deficiency of 3-β-hydroxysteroid dehydrogenase, another rare form of CAH, is the blockage in the conversion of pregnenolone to progesterone, 17-hydroxypregnenolone to 17-OHP, and DHEA to androstenedione. Therefore, male fetuses are under-virilized due to the defect in testosterone production, and female fetuses are over-virilized due to the accumulation of DHEA.
In CAH, due to 17-α-hydroxylase deficiency, androstenedione, 17-hydroxypregnenolone, 17-OHP, DHEA, androgen (testosterone, estrone, estradiol), and cortisol are low, while production of mineralocorticoid and its precursors including pregnenolone, 11-DOC, corticosterone, and 18-hydroxycorticosterone are increased. However, CAH due to 3-β-hydroxysteroid dehydrogenase deficiency is characterized by elevated ratio of 17-hydroxypregnenolone to 17-OHP, pregnenolone to progesterone, and DHEA to androstenedione.
- Differential diagnosis of congenital adrenal hyperplasia when used in conjunction with other intermediates of steroidogenesis, including 11-DOC, DHEA, 17-OHP, androstenedione and cortisol
- As an aid in diagnosis of 17-α-hydroxylase deficiency or 3-β-hydroxysteroid dehydrogenase deficiency
- As an aid in diagnosis of hirsutism or infertility in females
Increased in: Congenital adrenal hyperplasia due to 3-β-hydroxysteroid dehydrogenase deficiency
Decreased in: Congenital adrenal hyperplasia due to 17-α-hydroxylase deficiency
Adults
| Group | Reference Range (ng/dL) |
| Males | 55 – 455 |
| Females | 31 – 455 |
Children - Males:
| Age | Reference Range (ng/dL) |
| Premature (26–28 weeks) | 1219 – 9799 |
| Premature (29–36 weeks) | 346 – 8911 |
| Full term (1–5 months) | 229 – 3104 |
| 6–12 months | 221 – 1981 |
| 1–2 years | 35 – 712 |
| 2–4 years | < 249 |
| 5–6 years | < 319 |
| 7–9 years | < 188 |
| 10–12 years | < 393 |
| 13–15 years | 35 – 465 |
| 16–17 years | 32 – 478 |
Children - Females
| Age | Reference Range (ng/dL) |
| Premature (26–28 weeks) | 1219 – 9799 |
| Premature (29–36 weeks) | 346 – 8911 |
| Full term (1–5 months) | 229 – 3104 |
| 6–12 months | 221 – 1981 |
| 1–2 years | 35 – 712 |
| 2–4 years | < 280 |
| 5–6 years | < 350 |
| 7–9 years | < 213 |
| 10–12 years | < 399 |
| 13–15 years | < 408 |
| 16–17 years | < 424 |
Tanner Stages - Males
| Tanner Stage | Reference Range (ng/dL) |
| Stage I | < 209 |
| Stage II | < 356 |
| Stage III | < 451 |
| Stage IV–V | 35 – 478 |
Tanner Stages - Females
| Tanner Stage | Reference Range (ng/dL) |
| Stage I | < 236 |
| Stage II | < 368 |
| Stage III | < 431 |
| Stage IV–V | < 413 |
Serum (SST).
Stability
- Refrigerated: 7 days
- Frozen- 28 days
- Horm Res. 2000;53:68-71. [PMID:10971091]
- Ann Clin Lab Sci. 2001;31:199-204. [PMID:11337910]
- Clin Chem. 2006;52:1559-67. [PMID:16777916]
- Stewart PM, Krone NP. “The Adrenal Cortex.” Williams Textbook of Endocrinology, 12th ed. Saunders Company: Philadelphia, PA; 2011. Page 479-544
- Demers LM. “The Adrenal Cortex.” Textbook of Clinical Chemistry and Molecular Diagnostics, 4th ed. 2006. Page 2003-52.